Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9223970 | 0.89 | CTSK (0.56) | RENCAPN1CTSKCTSBCTSL | |
| SCHEMBL8441060 | 0.89 | CTSL (0.55) | CAPN1ALDH1A1CTSKCTSBCTSL | |
| SCHEMBL18342569 | 0.88 | CTSK (0.55) | RENCAPN1CTSKCTSBCTSL | |
| SCHEMBL20263594 | 0.88 | CTSK (0.55) | RENCAPN1CTSKCTSBCTSL | |
| SCHEMBL10868800 | 0.88 | CAPN1 (0.59) | RENCAPN1ALDH1A1THRBCYP2C9 | |
| SCHEMBL10347011 | 0.88 | CAPN1 (0.59) | RENCAPN1ALDH1A1THRBCYP2C9 | |
| SCHEMBL1509254 | 0.88 | CTSK (0.57) | RENCAPN1CTSKCTSBCTSL | |
| SCHEMBL11781682 | 0.87 | ALDH1A1 (0.64) | RENCAPN1ALDH1A1THRBCYP2C9 | |
| SCHEMBL9220259 | 0.87 | REN (0.55) | RENKLK5CTSKCTSBCTSL | |
| SCHEMBL10432854 | 0.87 | ITGB3 (0.56) | CAPN1CTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313594-A1 | TWO-RESIDUE-EXTENDED PEPTIDE AND METHOD FOR PRODUCING SAME | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4527846-A1 | TWO-RESIDUE-EXTENDED PEPTIDE AND METHOD FOR PRODUCING SAME | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023223714-A1 | TWO-RESIDUE-EXTENDED PEPTIDE AND METHOD FOR PRODUCING SAME | 国立大学法人東海国立大学機構 | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313594-A1 | TWO-RESIDUE-EXTENDED PEPTIDE AND METHOD FOR PRODUCING SAME | NPPA, NGLY1, ANPEP | REN 464/4885KLK5 1696/4885CAPN1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.